Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NXR1
UPID:
NDE1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NXR1; Q49AQ2
Background:
Nuclear distribution protein nudE homolog 1 plays a pivotal role in centrosome duplication, mitotic spindle formation, and cerebral cortex development. It regulates neuron production by controlling mitotic spindle orientation during cortical neuronal progenitor division.
Therapeutic significance:
Linked to Lissencephaly 4 and Microhydranencephaly, understanding its function could unveil new therapeutic strategies for these severe neurodevelopmental disorders.